Mucositis and non-invasive markers of small intestinal function

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Mucositis, a chemotherapy side effect, causes gastrointestinal ulceration due to chemotherapy's lack of cell discrimination.
• Understanding small intestinal mucositis pathobiology is crucial for developing effective treatments.
• The small intestine's inaccessibility hinders conventional assessment methods.

Purpose of the Study:

• To evaluate non-invasive biomarkers for assessing small intestinal function.
• To establish the 13C-sucrose breath test (SBT) as a superior biomarker for chemotherapy-induced mucositis.
• To explore the clinical application of SBT in monitoring mucositis in cancer patients.

Main Methods:

• Review of non-invasive biomarkers including small intestinal permeability, H2 breath tests, serum citrulline tests, and the 13C-sucrose breath test (SBT).
• Focus on SBT's ability to measure sucrase activity, correlating with villus blunting and crypt disruption.
• Analysis of SBT's application in detecting mucositis induced by various chemotherapy agents and monitoring anti-mucositis treatments.

Main Results:

• The 13C-sucrose breath test (SBT) shows potential as an appropriate biomarker for chemotherapy-induced mucositis.
• SBT effectively measures decreased sucrase activity linked to small intestinal damage.
• Previous studies demonstrate SBT's success in detecting mucositis and monitoring treatment efficacy.

Conclusions:

• The 13C-sucrose breath test (SBT) is proposed as a superior biomarker for assessing small intestinal function.
• SBT can be effectively applied in clinical settings for monitoring mucositis development in cancer patients undergoing chemotherapy.
• Further clinical validation of SBT could improve patient care and treatment strategies for mucositis.